title: Renal transplantation across the ABO barrier using A2 kidneys.
abstract: BACKGROUND
  The waiting list for cadaveric kidney transplantation has continued to grow, and with the relative scarcity of cadaver donors, the median waiting time for patients in the United States increased to 824 days in 1994. The median waiting times for patients with blood groups B or O were 1329 and 1007 days, respectively. Allocation of blood group A2 kidneys (20% of group A) to blood group O and B patients expands their potential donor pool and shortens their waiting time for a kidney transplantation.
  
  
  METHODS
  Between May 1991 and June 1998, we transplanted 15 A2 kidneys into 6 blood group O and 9 blood group B patients. Anti-A isoagglutinins were measured before transplantation, and patients with anti-A1 titers > or = 1:8 underwent plasmapheresis (PP).
  
  
  RESULTS
  One patient with high titer anti-A antibodies, who did not receive PP, lost her allograft because of hyperacute rejection. Allograft function was excellent in the remaining 14 patients, with a mean serum creatinine level of 1.7 (+/-0.89) mg/dl at 1 month and 1.3 (+/-0.34) mg/dl at 1 year. The actuarial 1-year graft survival rate was 93.3+/-6.4% and the patient survival rate was 100%.
  
  
  CONCLUSIONS
  We conclude that the allocation of blood group A2 kidneys for blood group O and B recipients is a practical way to expand the donor pool for these transplant candidates. PP may be important for reducing the levels of anti-A1 and anti-A2 antibodies and for reducing the risk of hyperacute rejection. Splenectomy seems to be unnecessary.
authors.affiliation: Department of Medicine, Oregon Health Sciences University, Portland 97201, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Alkhunaizi
authors.forename: A M
authors.initials: AM
authors.lastname: de Mattos
authors.forename: J M
authors.initials: JM
authors.lastname: Barry
authors.forename: W M
authors.initials: WM
authors.lastname: Bennett
authors.forename: D J
authors.initials: DJ
authors.lastname: Norman
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology / Q000502:physiology*; D000328:Adult; D002102:Cadaver; D005260:Female; D006084:Graft Rejection / Q000097:blood; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D019520:Living Donors; D008297:Male; D008875:Middle Aged
chemical_list: D000017:ABO Blood-Group System; D007074:Immunoglobulin G; D007518:Isoantibodies